![]() ![]() Three non-vitamin K oral anticoagulants (NOACs)-rivaroxaban ( Xarelto), dabigatran ( Pradaxa) and apixaban ( Eliquis)-were first approved for use in Australia by the Therapeutic Goods Administration (TGA) between 20 and listed on the Pharmaceutical Benefits Scheme (PBS), Australia’s national drug subsidy programme between 20. ![]() 2 There is also an association between increased prescribing of brand-name medications and exposure to industry-sponsored events, particularly those serving meals and beverages. 1 Exposure to information presented at these types of events is associated with greater numbers of prescriptions. Sponsors provided attendees with free dinners, lunches, refreshments, beverages, and some travel and accommodation to overseas locations amounting to over $A286 million. Between October 2011 to September 2015, 47 pharmaceutical companies sponsored more than 116 000 events with over 3 million attendances by Australian doctors, nurses, pharmacists and specialists. ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |